impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15

 

  1. Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.
  2. Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.
  3. Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.
  4. Rheumatology Division, Hospital Universitario Txagorritxu, Vitoria, Araba, University of the Basque Country, Araba, Spain.
  5. Rheumatology Division, Hospital Universitario Sierrallana, Torrelavega, Cantabria, Spain.
  6. Rheumatology Division, Hospital Universitario de La Princesa, IIS-Princesa, Universidad Autónoma de Madrid (UAM), Madrid, Spain.
  7. Rheumatology Division, Hospital Universitario de La Princesa, IIS-Princesa, Universidad Autónoma de Madrid (UAM), Madrid, Spain.
  8. Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.
  9. Epidemiology and Computational Biology Department, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander;
  10. Rheumatology Division, Hospital Universitario Basurto, Bilbao, Bizkaia, Spain.
  11. Rheumatology Division, Hospital Universitario Basurto, Bilbao, Bizkaia, Spain.
  12. The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Servizo Galego de Saude and Instituto de Investigación Sanitaria de Santiago, Santiago University Clinical Hospital, Santiago de Compostela, Spain.
  13. Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.
  14. Rheumatology Division, Hospital Universitario de la Princesa, IIS-Princesa, Cátedra UAM-ROCHE, EPID Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain.
  15. Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, School of Medicine, University of Cantabria, Santander, Spain. miguelaggay@hotmail.com

CER12982
2020 Vol.38, N°6
PI 1201, PF 1205
Full Papers

purchase article

PMID: 32452351 [PubMed]

Received: 29/11/2019
Accepted : 28/01/2020
In Press: 20/05/2020
Published: 03/12/2020

Abstract

OBJECTIVES:
Leptin is an adipokine that participates in the regulation of the immune and inflammatory response. Chronic systemic inflammation contributes to the development of cardiovascular (CV) disease in rheumatoid arthritis (RA). In this study, we aimed to assess the short-term effect of the anti-IL-6 receptor tocilizumab (TCZ) administration on circulating leptin concentrations in patients with RA, as well as the potential association of leptin with CV risk factors and demographic and clinical characteristics of these patients.
METHODS:
We recruited 50 consecutive non-diabetic patients with RA undergoing periodic treatment with TCZ. Leptin serum levels were determined by a commercial immunoassay kit in samples obtained immediately prior to (pre-infusion) and 60 minutes after the end of a TCZ intravenous infusion (post-infusion).
RESULTS:
A significant reduction of leptin levels was observed following the TCZ infusion (9.24±7.98 ng/mL vs. 7.92±7.32 ng/mL, pre- and post-infusion, respectively, p=0.002). Additionally, there was a strong positive correlation between body mass index of RA patients and basal levels of leptin (r=0.56; p=0.0001). Moreover, high basal levels of leptin in RA patients were associated with female sex (p=0.006), obesity (p<0.001) and rheumatoid factor negative status (p=0.006).
CONCLUSIONS:
Our study disclosed a short-term effect of anti-IL-6 therapy on leptin serum levels in RA patients. Decreased leptin levels may explain the beneficial effect of anti-IL-6 blockade on CV disease associated to RA.

Rheumatology Article